Muramyl Dipeptide-Presenting Polymersomes as Artificial Nanobacteria to Boost Systemic Antitumor Immunity DOI

Guanhong Cui,

Yinping Sun,

Shenqiang Wang

и другие.

ACS Applied Materials & Interfaces, Год журнала: 2024, Номер 16(45), С. 61655 - 61663

Опубликована: Ноя. 5, 2024

The clinical efficacy of cancer vaccines is closely related to immunoadjuvants that play a crucial role in magnifying and prolonging the immune response. Muramyl dipeptide (MDP), minimal conserved peptidoglycan found almost all bacteria, can trigger robust activation by uniquely antagonizing nucleotide-binding oligomerization domain 2 (NOD2) pathway. However, its effectiveness has been hindered limited solubility, poor membrane penetration, rapid clearance from body. Here, we introduce MDP-presenting polymersomes as artificial nanobacteria (NBA) boost antitumor NBA, featuring abundant MDP molecules, induces superior stimulation cells including macrophages bone marrow-derived dendritic (BMDCs) compared free MDP, likely via facilitating cell uptake cooperatively stimulating systemic NOD2 signaling. Importantly, administration NBA significantly enhances chemo-immunotherapy B16-F10 melanoma-bearing mice pretreated with doxorubicin reversing immunosuppressive tumor microenvironment. Furthermore, carrying ovalbumin lysates OVA-IgG antibody production effectively inhibit growth, respectively. hold great promise potent immunoadjuvant for immunotherapy.

Язык: Английский

Co-activating STING-TLR9 pathways promotes radiotherapy-induced cancer vaccination DOI
Yuling Sun, Liang Liu,

Huilan He

и другие.

Journal of Controlled Release, Год журнала: 2025, Номер 379, С. 327 - 343

Опубликована: Янв. 14, 2025

Язык: Английский

Процитировано

1
Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines DOI Open Access
Yuanyuan Li, Yuxing Xu,

Wenwen Su

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 184, С. 117897 - 117897

Опубликована: Фев. 7, 2025

Язык: Английский

Процитировано

1
Polymersomal Poly(I:C) Self‐Magnifies Antitumor Immunity by Inducing Immunogenic Cell Death and Systemic Immune Activation DOI
Jingyi Wang, Beibei Guo, Zhiwei Sun

и другие.

Advanced Healthcare Materials, Год журнала: 2024, Номер unknown

Опубликована: Июнь 19, 2024

Immunotherapy has emerged as a powerful weapon against lung cancer, yet only fraction of patients respond to the treatment. Poly(I:C) (PIC) effectively triggers both innate and adaptive immunity. It can also induce immunogenic cell death (ICD) in tumor cells. However, its efficacy is hindered by instability vivo limited cellular uptake. To address this, PIC encapsulated cRGD-functionalized polymersomes (t-PPIC), which significantly increases stability uptake, thus activating dendritic cells (DCs) inducing apoptosis vitro. In murine LLC model, systemic administration t-PPIC suppresses growth leads survival benefits, with 40% mice becoming tumor-free. Notably, provokes stronger ICD tissue elicits more potent stimulation DCs, recruitment natural killer (NK) cells, activation CD8

Язык: Английский

Процитировано

4
Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia DOI
Peng Zhang,

Tanzhen Wang,

Guanhong Cui

и другие.

Advanced Materials, Год журнала: 2024, Номер unknown

Опубликована: Авг. 22, 2024

Abstract Hematological malignancies (HM) like acute myeloid leukemia (AML) are often intractable. Cancer vaccines possibly inducing robust and broad anti‐tumor immune responses may be a promising treatment option for HM. Few effective against blood cancers are, however, developed to date partly owing insufficient stimulation of dendritic cells (DCs) in the body lacking appropriate tumor antigens (Ags). Here it is found that systemic multifunctional nanovaccines consisting nucleotide‐binding oligomerization domain‐containing protein 2 (NOD2) Toll‐like receptor 9 (TLR9) agonists – muramyl dipeptide (MDP) CpG, cell lysate (TCL) as Ags (MCA‐NV) induce potent immunity AML. MCA‐NV show complementary DCs prime homing lymphoid organs following administration. Of note, orthotopic AML mouse models, intravenous infusion different vaccine formulations elicits substantially higher anti‐AML efficacies than subcutaneous Systemic cure 78% mice elicit long‐term memory with 100% protection from rechallenging cells. can also serve prophylactic same These utilizing patient TCL dual adjuvants strong, durable, provide personalized immunotherapeutic strategy other

Язык: Английский

Процитировано

4
A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity DOI
Liping Qu,

Guanhong Cui,

Yinping Sun

и другие.

Advanced Materials, Год журнала: 2024, Номер unknown

Опубликована: Авг. 28, 2024

Personalized cancer vaccines based on tumor cell lysates offer promise for immunotherapy yet fail to elicit a robust therapeutic effect due the weak immunogenicity of antigens. Autophagosomes, obtained from pleural effusions and ascites patients, have been identified as abundant reservoirs neoantigens that exhibit heightened immunogenicity. However, their potential personalized constrained by suboptimal lymphatic-targeting performances challenges in antigen-presenting endocytosis. Here,a reinforced biomimetic autophagosome-based (BAPs) nanovaccine generated precisely amalgamating autophagosome-derived two types adjuvants capable targeting lymph nodes is developed potently antitumor immunity. The redox-responsive BAPs facilitate cytosolic vaccine opening within cells, thereby exposing antigens stimulate strong immune response. evoke broad-spectrum T-cell responses, culminating effective eradication 71.4% established tumors. Notably, vaccination triggers enduring responses confer protection, with 100% mice shielded against rechallenge significant reduction incidence 87.5%. Furthermore, synergize checkpoint blockade therapy inhibit growth poorly immunogenic breast model. approach presents powerful formula high versatility immunotherapy.

Язык: Английский

Процитировано

4
Autologous Nanovaccine Induces Immunogenic Domino Effect to Prevent Postoperative Recurrence of Orthotopic Glioblastoma DOI Open Access

Jinghong Yang,

Ke Zhang, Guangliang Zhang

и другие.

Advanced Functional Materials, Год журнала: 2025, Номер unknown

Опубликована: Фев. 3, 2025

Abstract Glioblastoma (GBM), the most aggressive form of primary intracranial tumors, poses significant challenges for effective treatment. The highly invasive characteristics GBM render complete tumor resection exceedingly difficult and frequently lead to postoperative recurrence. To address this issue, a novel autologous nano vaccine is developed convert immunosuppressive microenvironment into an active immune landscape through immunogenic domino effect, thereby targeting residual cells preventing This nanovaccine formulated by co‐loading lipopolysaccharide (LPS) glioblastoma cell lysates (GCL) layered double hydroxide (LDH) nanosheets, which are subsequently integrated within injectable alginate hydrogel create LLGA‐Gel. exploits potential GCL in conjunction with immunostimulatory properties LPS induce pyroptotic death, enhance dendritic maturation, promote macrophage polarization toward M1 phenotype; these effects culminate increased CD8 + T infiltration reduced Foxp3 Tregs at site. In vivo experiments demonstrate that not only enhances efficacy death but also significantly amplifies response, markedly reducing recurrence orthotopic GBM. study underscores promise nanotechnology‐enhanced immunotherapy developing nanovaccines against

Язык: Английский

Процитировано

0
Melanoma immunotherapy by nanosphere-vaccine elicited CD4+ and CD8+ T-cell response for tumor regression DOI

Kalpana Javvaji,

Venugopal Vangala, Suresh Babu Sayana

и другие.

Nanomedicine Nanotechnology Biology and Medicine, Год журнала: 2025, Номер unknown, С. 102817 - 102817

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Tumor cell-derived engineered exosome enhances effective immunotherapy for orthotopic glioblastoma and its recurrences DOI Creative Commons
Shanshan Li,

Dongya Zhang,

Yibin Wang

и другие.

Nano Today, Год журнала: 2025, Номер 63, С. 102748 - 102748

Опубликована: Апрель 8, 2025

Язык: Английский

Процитировано

0
Dual and multi-immune activation strategies for emerging cancer immunotherapy DOI
Ying Zhang, Liang Liu,

Huilan He

и другие.

Materials Today, Год журнала: 2024, Номер unknown

Опубликована: Сен. 1, 2024

Язык: Английский

Процитировано

2
Nano‐ and Micro‐Platforms in Therapeutic Proteins Delivery for Cancer Therapy: Materials and Strategies DOI Creative Commons
Huijie Han, Hélder A. Santos

Advanced Materials, Год журнала: 2024, Номер unknown

Опубликована: Сен. 12, 2024

Abstract Proteins have emerged as promising therapeutics in oncology due to their great specificity. Many treatment strategies are developed based on protein biologics, such immunotherapy, starvation therapy, and pro‐apoptosis while some biologics entered the clinics. However, clinical translation is severely impeded by instability, short circulation time, poor transmembrane transportation, immunogenicity. Micro‐ nano‐particles‐based drug delivery platforms designed solve those problems enhance therapeutic efficacy. This review first summarizes different types of proteins research stages, highlighting administration limitations. Next, various micro‐ nano‐particles described demonstrate how they can overcome The potential then explored efficacy combinational therapies. Finally, challenges future directions carriers discussed for optimized delivery.

Язык: Английский

Процитировано

1